Form 4: Donenberg Phillip B. reports acquisition/exercise transactions in SNSE

Rhea-AI Filing Summary

Donenberg Phillip B. reported acquisition or exercise transactions in a Form 4 filing for SNSE. The filing lists transactions totaling 1,900 shares. Following the reported transactions, holdings were 1,900 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donenberg Phillip B.

(Last) (First) (Middle)

C/O SENSEI BIOTHERAPEUTICS, INC.

1405 RESEARCH BLVD, SUITE 125

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$9.09	02/13/2026		A		1,900		(1)	02/12/2036	Common Stock	1,900	$0	1,900	D

Explanation of Responses:

1. The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or February 13, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Phillip B. Donenberg	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SNSE director Phillip B. Donenberg report?

Phillip B. Donenberg reported receiving a stock option grant for 1,900 shares. The derivative award gives him the right to purchase Sensei Biotherapeutics (SNSE) common stock at a set exercise price, subject to a multi-year vesting schedule tied to continued service.

How many SNSE stock options were granted to Phillip B. Donenberg?

He was granted stock options covering 1,900 shares of Sensei Biotherapeutics common stock. This entire amount is reflected as derivative securities beneficially owned following the reported transaction, subject to vesting over time as detailed in the award’s terms.

What is the exercise price of Phillip B. Donenberg’s SNSE stock options?

The stock options have an exercise price of $9.09 per share. This means he can purchase Sensei Biotherapeutics (SNSE) common stock at $9.09 if and when the options vest and he chooses to exercise them in the future.

When do Phillip B. Donenberg’s SNSE options fully vest?

The options vest in 36 equal monthly installments and are fully vested on February 13, 2029. Vesting depends on his continuous service with Sensei Biotherapeutics through each monthly vesting date specified in the award’s terms.

Is Phillip B. Donenberg’s SNSE option grant a purchase or an award?

The transaction is reported as a grant or award, not an open-market purchase. It is coded as an acquisition of derivative securities, reflecting compensation in the form of stock options subject to specified vesting conditions over three years.

How is ownership of the SNSE stock options reported for Phillip B. Donenberg?

Ownership of the 1,900 stock options is reported as direct. Following the grant, the Form 4 shows 1,900 derivative securities beneficially owned directly, indicating the award is tied personally to the director rather than an indirect holding entity.